ProCE Banner Activity

Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

Podcast Episodes

Audio podcast with key highlights on current and emerging data for the use of oral SERDS in patients with HR+/HER2- ESR1-mutated advanced breast cancer. Listen to experts put new trial results into context and cover practical perspectives and takeaway points for your everyday practice.

Released: January 31, 2025

Expiration: July 30, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly

AstraZeneca

Lilly

Faculty Disclosure

Primary Author

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Virginia Kaklamani, MD, DSc: consultant/advisor/speaker: AstraZeneca, Genentech, Gilead, Menarini.

Erica L. Mayer, MD, MPH, FASCO

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Erica L. Mayer, MD, MPH, FASCO: consultant/advisor/speaker: AstraZeneca, Lilly, Novartis.

Laura Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: AstraZeneca, Genentech, Gilead, Lilly, Merck; other (travel support): Lilly.